Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Targeted Photoactivatable Nanocells to Image and Treat Metastic Ovarian Cancer


Biography

Overview
This application addresses broad Challenge Area (13) Smart Biomaterials - Theranostics and specific Challenge Topic, 13-CA-102: Nanotechnology-based multi-functional materials for theranostic applications. The long term goal of this research is to develop mechanism and nanotechnology-based image-guided combination regimens with photodynamic therapy (PDT), an FDA approved treatment for certain cancers and in clinical trials for Ovarian Cancer (OvCa). The poor survival for OvCa stems in large part from residual tumor following surgery and chemotherapy leading to the disease recurrence and due to resistance to radiation and chemotherapy. A minimally invasive imaging modality with sensitivity and resolution to detect sub-millimeter OvCa nodules associated with recurrent disease, early in the treatment cycle would allow for timely disease re-assessment and the initiation of additional treatments if needed. Optical microendoscopy is a minimally invasive imaging modality with high sensitivity and micron-scale resolution. We have developed such a fluorescence microendoscope and shown it is capable of detecting small tumor nodules. We have also demonstrated that PDT sensitizes tumors to anti-VEGF (Avastin) treatment and that this combination (PDT and Avastin) is more effective when Avastin is delivered intracellularly in a nanoconstruct. The hypothesis underlying this proposal is that PDT combined with intracellular targeting of the VEGF pool will be a valuable combination treatment that will be most useful when incorporated with an imaging system that can monitor treatment response. Our strategy is to use a Theranostic Nanocell (TNC) that encapsulates Avastin and the PDT agent benzoporphyrin derivative as therapeutic components. The TNC targets Epidermal Growth Factor Receptor (EGFR) on OvCa cells via fluorescent indocyanine green-labeled anti-EGFR antibody (Cetuximab /C225) and serves as the diagnostic component of TNC. Encapsulation of Avastin inside these molecularly targeted nano-constructs should reduce the severe systemic toxicity of this drug, which is often lethal. The goals will be realized in 3 specific aims: 1) Synthesis and characterization of TNC, 2) Investigate the effect of theranostic nanocell in 3D cell culture models to obtain effective doses and 3) Evaluate the in vivo efficacy of the TNC to detect tumor nodules and establish TNC biodistribution in a murine model of OvCa using microendoscopy. In order to complete the project in the two year funding period, this proposal is focused primarily on developing and characterizing the TNC in vitro with a minor in vivo component. However, if successful, the results will be further substantiated in an extensive animal/human study and the findings of this study will impact a large proportion of OvCa patients with adaptability of the multifunctional platform to other diseases. Major deliverables of this proposal will be i) TNC fabrication and dosing to image and destroy tumor nodules in vitro in 3D cultures as well as detect these disseminated nodules in vivo, and ii) Fluorescence microendoscope for TNC-based sensitive and specific detection of the micrometastatic OvCa.

PUBLIC HEALTH RELEVANCE: Current methods to treat OvCa following surgery have failed to drastically improve patient survival and quality of life. Our method will not only help locate the microscopic residual disease but also selectively destroy it with multiple drugs and with reduced side-effects. This study has the potential to improve patient care and could result in the development of a new standard of management for the patients with OvCa following surgery.

RC1CA146337
HASAN, TAYYABA

Time
2009-09-30
2012-09-29
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.